Pharmaceuticals

Pharmalot Ed Silverman

STAT Plus: U.S. agency slaps down a J&J plan to switch payments for 340B hospitals

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

The Readout LOUD Adam Feuerstein, Elaine Chen, and Allison DeAngelis

Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides

Biotech Andrew Joseph

STAT Plus: U.K.’s cost-effectiveness agency gives negative review of Alzheimer’s drug Leqembi

Politics John Wilkerson

STAT Plus: Congressional probe questions clinical trials run in China, citing army involvement

Biotech Elaine Chen

STAT Plus: Lilly’s Zepbound slashed risk of developing diabetes

First Opinion Michael Banks

Improving the FDA-EMA parallel scientific advice program to advance complex generics

Pharmalot Ed Silverman

STAT Plus: Will the FTC challenge a deal that would give Novo Nordisk control of some Catalent plants?

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

First Opinion Peter Staley

Gilead must be held accountable for the harm caused by ‘patent hopping’ an HIV treatment

Politics Rachel Cohrs Zhang

STAT Plus: What do Biden’s drug price comparisons reveal? Not much

Health Jason Mast

STAT Plus: Antiviral used for mpox no better than placebo, NIH says

Morning Rounds Theresa Gaffney

New Medicare drug prices, antimicrobial-resistant meningitis, unlucky American women

Politics John Wilkerson and Rachel Cohrs Zhang

STAT Plus: Medicare drug price negotiation didn’t benefit Biden — but it may help Harris

Pharma Rachel Cohrs Zhang

STAT Plus: Medicare announces drug prices for historic first round of negotiations

Biotech Matthew Herper

STAT Plus: Eli Lilly’s billions: Can the world’s most valuable pharma company keep inventing drugs at this pace?

First Opinion Suzanne Robotti

The FDA should withdraw approval of more than 400 tainted medicines

Pharma Isabella Cueto

STAT Plus: FDA approves EpiPen alternative, a nasal spray for anaphylaxis

Morning Rounds Brittany Trang

Morning Rounds: Another Ebola outbreak?

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Politics Rachel Cohrs Zhang

STAT Plus: Judge rules against Chamber of Commerce in Medicare drug negotiation lawsuit

Pharmalot Ed Silverman

STAT Plus: A U.K. trade group scolds Novo again — this time for remarks made by its CEO

Pharmalot Ed Silverman

STAT Plus: FDA scolds Bristol Myers over a misleading website for a cancer treatment

First Opinion Fred D. Ledley

Give pharmaceutical execs the benefit of doubt — but they need to work for it

Pharma Andrew Joseph

STAT Plus: Supply issues weigh on Novo Nordisk as drugmaker stumbles with quarterly report

Pharmalot Ed Silverman

STAT Plus: North Carolina urges HHS to license Novo and Lilly obesity drugs as a way to lower costs

Morning Rounds Theresa Gaffney

Morning Rounds: The ‘very risky business’ of buying weight loss drugs online

Health tech Katie Palmer

STAT Plus: Weight loss drugs without a prescription? Study warns it’s a ‘very risky business’

Morning Rounds Theresa Gaffney

Morning Rounds: Grindr gets into health care lobbying